Overview

AMT-253 in Patients With Advanced Solid Tumours

Status:
RECRUITING

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

Phase:

PHASE1

Details

Lead Sponsor:

Multitude Therapeutics Inc.

Treatments:

Injections